In murine models of retinitis pigmentosa, minocycline attenuates microglial activation and reduces CCR2+ monocyte recruitment, thereby preserving photoreceptors and maintaining visual function; open-label clinical observations in RP patients report measurable visual function benefits over 6-12 months (27, 94). Here, CCR2 is linked to retinitis pigmentosa 1.